Journal profile · ONCOLOGY
Melanoma Management
ISSN 2045-0885 · eISSN 2045-0893 · Future Medicine Ltd · United Kingdom
Melanoma Management: CAS Zone 4 · Medicine (2026 Xinrui edition); impact factor 1.1 (journal website); fully open access; APC about USD 1,415; median 119 days to acceptance (18 articles, last 24 months); acceptance rate 100% (journal website); 14 articles in 2025; indexed in ESCI and Scopus.
Scope
Aims, scope and focus
Melanoma Management is published by Future Medicine Ltd and is classed under Medicine in the CAS Journal Ranking. By OpenAlex counts of its recent articles, its largest topics are Cutaneous Melanoma Detection and Management, Melanoma and MAPK Pathways and CAR-T cell therapy research, together about 53.1% of its articles. Its main subfields are Oncology. (generated from OpenAlex topic counts and CAS ranking data)
Skin cancer is on the rise. According to the World Health Organization, 132,000 melanoma skin cancers occur globally each year. While early-stage melanoma is usually relatively easy to treat, once disease spreads prognosis worsens considerably. Therefore, research into combating advanced-stage melanoma is a high priority. New and emerging therapies, such as monoclonal antibodies, B-RAF and KIT inhibitors, antiangiogenic agents and novel chemotherapy approaches hold promise for prolonging survival, but the search for a cure is ongoing. Melanoma Management publishes high-quality peer-reviewed articles on all aspects of melanoma, from prevention to diagnosis and from treatment of early-stage disease to late-stage melanoma and metastasis. The journal presents the latest research findings in melanoma research and treatment, together with authoritative reviews, cutting-edge editorials and perspectives that highlight hot topics and controversy in the field. Independent drug evaluations assess newly approved medications and their role in clinical practice. Key topics covered include: Risk factors, prevention and sun safety education Diagnosis, staging and grading Surgical excision of melanoma lesions Sentinel lymph node biopsy Biological therapies, including immunotherapy and vaccination Novel chemotherapy options Treatment of metastasis Prevention of recurrence Patient care and quality of life Melanoma Management delivers an accessible overview of current and future melanoma management options in a concise format that is ideal for the busy clinician. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal's Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including COPE, ICMJE and GPP3.
From the journal's Aims & Scope
Research area (LetPub): ONCOLOGY
Editorial board by country: none in mainland China; most named United States 1, United Kingdom 1, Austria 1 (3 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Cutaneous Melanoma Detection and ManagementMedicine23.7%
- Melanoma and MAPK PathwaysBiochemistry, Genetics and Molecular Biology17.6%
- CAR-T cell therapy researchMedicine11.8%
- Cancer Immunotherapy and BiomarkersMedicine11.1%
- Immunotherapy and Immune ResponsesImmunology and Microbiology10.2%
- Nonmelanoma Skin Cancer StudiesMedicine4.6%
- Skin Protection and AgingMedicine2.6%
- Ocular Oncology and TreatmentsMedicine2%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Not covered
Not covered by this edition.
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
ESCIScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
Web of SciencePMCEmbasePublisher website
Other: EMCare, Research Alert
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher) 2025
- 1.1Publisher website ·
- 5-year impact factor (publisher) 2025
- 2.2Publisher website ·
- CiteScore 2026-06
- 1.2LetPub ·
- CiteScore (publisher) 2025
- 1.2Publisher website ·
- SJR 2026-06
- 0.4LetPub ·
- SJR (publisher) 2025
- 0.4Publisher website ·
- SNIP 2026-06
- 0.55LetPub ·
- SNIP (publisher) 2025
- 0.55Publisher website ·
- h-index
- 25OpenAlex ·
- i10-index
- 70OpenAlex ·
- 2-year mean citedness
- 1.68OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 13LetPub ·
- Downloads per year (publisher)
- 34,000Publisher website ·
- Downloads per year (publisher) 2025
- 34,000Publisher website ·
Articles by year OpenAlex count · 218 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 1 | 1 | 2 |
| 2025 | 14 | 14 | 19 |
| 2024 | 7 | 7 | 16 |
| 2023 | 4 | 4 | 19 |
| 2022 | 4 | 4 | 18 |
| 2021 | 6 | 6 | 44 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
119 daysMedian, submission to acceptance · P25–P75 76 days – 214 days
- Acceptance to online
- median 18 days (18 articles)
- Submission to online
- median 130 days
- Sample
- 18 articles with submission and acceptance dates (18 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 13 weeksLetPub ·
- Acceptance rate (publisher)
- 100%Publisher website ·
- Acceptance rate (publisher) 2025
- 100%Publisher website ·
- Submission to first decision
- 17 daysPublisher website ·
- Submission to first decision 2025
- 17 daysPublisher website ·
- Submission to publication (journal-reported)
- about 13 weeksDOAJ ·
- Peer review
- Double anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 1,415 | Yes | CC BY-NC-ND, CC BY | |
| OpenAlex | USD 1,415 | — | — | |
| LetPub | USD 1,415 | Yes | — | |
| Publisher website | Yes, amount not published | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Policy excerpts from the journal's websiteOpen access
- Open access Open access
Fully open access journal; only publishes open access articles. Model summary
Melanoma Management is an open access journal and only publishes open access articles. Publishing open access means that your article will be free to access online immediately on publication, increasing the visibility, readership, and impact of your research. Why choose open access? Increase the discoverability and readership of your article Make an impact and reach new readers, not just those wit…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Future Medicine Ltd
- Country or region
- United Kingdom
- Language
- English
- ISSN
- 2045-0885
- Electronic ISSN
- 2045-0893
- Latest issue on the website
- Volume 13, Issue 1 (2026)
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗Publisher website
- Author guidelines ↗DOAJ
- Aims & Scope ↗DOAJ
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗DOAJ
- Editorial board ↗DOAJ
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Melanoma Management
What CAS zone is Melanoma Management in?
In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Melanoma Management?
The journal's website gives an impact factor of 1.1 (2025); this is the journal's own figure, as LetPub lists none for it; CiteScore 1.2, h-index 25.
How long does peer review take at Melanoma Management?
Based on the dates recorded on 18 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 119 days (interquartile range 76–214 days); authors report an average review time of about 13 weeks; the journal's website gives an acceptance rate of 100% (2025). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Melanoma Management based?
Of the 3 board members whose country the journal's board page names, none are in mainland China; the countries named most often are United States (1), United Kingdom (1) and Austria (1). Counted from the institutions listed on the board page; for reference only.
Which databases index Melanoma Management?
According to LetPub and DOAJ records, Melanoma Management is indexed in ESCI, Scopus and DOAJ. The journal's website also lists Web of Science, PMC and Embase; that list has not been checked against each database.
Is Melanoma Management open access, and what is the APC?
Melanoma Management is a fully open-access journal. APC about USD 1,415.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .